deltatrials
Completed PHASE3 NCT00057720

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Phase 3 Randomized Study of TLK286 (Telcyta) Versus Doxil/Caelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-1 (Assessment of Survival In Solid Tumors-1)]

Sponsor: Telik

Conditions Ovarian Neoplasms
Interventions TLK286 HCl for injection doxorubicin HCl liposome injection topotecan hydrochloride for injection
Updated 7 times since 2017 Last updated: Jul 21, 2011 Started: Jun 30, 2003 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

This PHASE3 trial investigates Ovarian Neoplasms and is currently completed. Telik leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Telik
Data source: Telik

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States, Abington, United States, Albuquerque, United States, Amarillo, United States, Ann Arbor, United States, Arlington, United States, Babylon, United States, Bahía Blanca, Argentina, Bairro Bom Fim, Brazil, Baldwin Park, United States and 201 more location s